Petros Pharmaceuticals Stock Current Valuation
| PTPIDelisted Stock | USD 0.03 0 13.35% |
Valuation analysis of Petros Pharmaceuticals helps investors to measure Petros Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Petros Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Petros Pharmaceuticals is based on 3 months time horizon. Increasing Petros Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Petros Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Petros Pink Sheet. However, Petros Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0305 | Real 0.029 | Hype 0.03 |
The intrinsic value of Petros Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Petros Pharmaceuticals' stock price.
Estimating the potential upside or downside of Petros Pharmaceuticals helps investors to forecast how Petros pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Petros Pharmaceuticals more accurately as focusing exclusively on Petros Pharmaceuticals' fundamentals will not take into account other important factors: Petros Pharmaceuticals Company Current Valuation Analysis
Petros Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Petros Pharmaceuticals Current Valuation | (1.42 M) |
Most of Petros Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Petros Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Petros Pharmaceuticals has a Current Valuation of (1.42 Million). This is 100.01% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The current valuation for all United States stocks is 100.01% higher than that of the company.
Petros Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Petros Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Petros Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Petros Pharmaceuticals by comparing valuation metrics of similar companies.Petros Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Petros Fundamentals
| Return On Equity | -5.71 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (2.80) % | ||||
| Operating Margin | (2.41) % | ||||
| Current Valuation | (1.42 M) | ||||
| Shares Outstanding | 2.14 M | ||||
| Shares Owned By Insiders | 7.39 % | ||||
| Shares Owned By Institutions | 6.79 % | ||||
| Number Of Shares Shorted | 12.35 M | ||||
| Price To Book | 0.45 X | ||||
| Price To Sales | 0.05 X | ||||
| Revenue | 5.11 M | ||||
| Gross Profit | 3.9 M | ||||
| EBITDA | (10.81 M) | ||||
| Net Income | (14.32 M) | ||||
| Cash And Equivalents | 13.3 M | ||||
| Cash Per Share | 0.64 X | ||||
| Total Debt | 7.39 M | ||||
| Debt To Equity | 0.31 % | ||||
| Current Ratio | 3.10 X | ||||
| Book Value Per Share | (17.73) X | ||||
| Cash Flow From Operations | (2.6 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (63.15) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 2.2 | ||||
| Market Capitalization | 265.45 K | ||||
| Total Asset | 10.64 M | ||||
| Retained Earnings | (113.21 M) | ||||
| Working Capital | (10.73 M) | ||||
| Net Asset | 10.64 M |
About Petros Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Petros Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Petros Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Petros Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Petros Pink Sheet
If you are still planning to invest in Petros Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Petros Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |